Actively Recruiting
RAPART in Locally Advanced Non-small Cell Lung Cancer Patients
Led by Capital Medical University · Updated on 2025-12-02
911
Participants Needed
1
Research Sites
149 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a Phase II/III randomized clinical trial of Radiosensitivity-Assisted Personalized Adaptive Radiotherapy Technology (RAPART) in locally advanced non-small cell lung cancer patients. The main objective is to test the overall improvement of overall survival (OS), progression free survival (PFS), and local progression free survival (LPFS) of unresectable stage III NSCLC under standard and non-standard mixed treatment conditions compared to conventional 60Gy radiotherapy.
CONDITIONS
Official Title
RAPART in Locally Advanced Non-small Cell Lung Cancer Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged over 18 years
- Pathologically confirmed non-small cell lung cancer
- All unresectable stage III non-small cell lung cancer, including stage changes after multidisciplinary team evaluation or treatment
- ECOG performance status between 0 and 2
- Participants may be treatment-naive or have received surgery, chemotherapy, immunotherapy, or targeted therapy
You will not qualify if you...
- Prisoners unable to undergo close clinical follow-up
- Participants with contraindications to radiation therapy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Hong Kong Shenzhen Hospital
Shenzhen, Guangdong, China, 518000
Actively Recruiting
Research Team
F
Feng-Ming (Spring) Kong
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here